Amalgamated Bank Cassava Sciences Inc Transaction History

Amalgamated Bank

$12.2 Billion
Q4 2024

A detailed history of Amalgamated Bank transactions in Cassava Sciences Inc stock. As of the latest transaction made, Amalgamated Bank holds 1,412 shares of SAVA stock, worth $3,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,412

Previous 1,412 -0.0%

Holding current value

$3,600

Previous $42,000 92.86%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$12.35 - $26.11 $1,074 - $2,271	87 Added 6.57%	1,412 $17,000
Q1 2024 Apr 23, 2024	SELL	$18.44 - $26.41 $79,089 - $113,272	-4,289 Reduced 76.4%	1,325 $27,000
Q4 2023 Feb 06, 2024	SELL	$12.64 - $30.11 $4,980 - $11,863	-394 Reduced 6.56%	5,614 $126,000
Q2 2023 Aug 11, 2023	BUY	$21.59 - $27.88 $14,810 - $19,125	686 Added 12.89%	6,008 $147,000
Q1 2023 May 02, 2023	SELL	$23.46 - $36.44 $18,814 - $29,224	-802 Reduced 13.1%	5,322 $128,000
Q3 2022 Nov 09, 2022	BUY	$16.33 - $51.06 $1,567 - $4,901	96 Added 1.59%	6,124 $256,000
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $3,633 - $8,117	-211 Reduced 3.38%	6,028 $170,000
Q1 2022 Jun 30, 2022	SELL	$32.6 - $53.05 $16,137 - $26,259	-495 Reduced 7.35%	6,239 $232,000
Q4 2021 Feb 15, 2022	SELL	$36.77 - $90.91 $2,647 - $6,545	-72 Reduced 1.06%	6,734 $294,000
Q3 2021 Oct 29, 2021	SELL	$41.79 - $135.3 $17,468 - $56,555	-418 Reduced 5.79%	6,806 $423,000
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $232,251 - $648,137	7,224 New	7,224 $617,000

Others Institutions Holding SAVA

# of Institutions

190

Shares Held

16.4M

Call Options Held

3.49M

Put Options Held

8.08M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $102M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Cassava Sciences Inc Transaction History